Erlotinib Active Not Recruiting Phase 1 Trials for Recurrent Skin Carcinoma / Recurrent Salivary Gland Carcinoma / Recurrent Head and Neck Carcinoma / Skin Squamous Cell Carcinoma / Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT00954226Standard-Dose or High-Dose Erlotinib Hydrochloride Before Surgery in Treating Patients With Head and Neck Cancer